Followers | 604 |
Posts | 24107 |
Boards Moderated | 3 |
Alias Born | 12/06/2009 |
Sunday, April 08, 2018 5:35:37 PM
1. CHINA
Guided Therapeutics Inc. granted its current Asian distributor Shenghuo Medical LLC an exclusive license to manufacture, sell, and distribute its LuViva cervical cancer scanning device and related disposables in China and several Southeast Asian countries, including Brunei Darussalam, Cambodia, Laos, Myanmar, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. Shenghuo has been GTI's distributor in China, Hong Kong, and Macau, and the license extends to manufacturing in those countries as well.
CHINA HAS A POTENTIAL 390 MILLION PATIENTS.
All told, Guided Therapeutics said it expects to bring in $47.9 million from the deal over 3 years.
2. TURKEY
Turkish distribution partner ITEM for the manufacture of patented single-patient-use Cervical Guides in Turkey.
In return for the license and manufacturing rights for Cervical Guides in Turkey, GTHP will receive fees totaling $3,000,000 in 2018. In addition, ITEM will pay GTHP a royalty for each Cervical Guide made and sold exclusively in Turkey and ITEM will be obligated to purchase 600 LuViva Advanced Cervical Scans and produce 3 million Cervical Guides for the Turkish market over the next five years.
$14.4 million multi-year contract with Turkey for 1.1 million disposables
3. INDIA
(HOW MUCH MONEY WILL THE INDIA DEAL BE WORTH? THEY ARE SECOND TO CHINA IN TERMS OF # OF POTENTIAL PATIENTS)
Plans for commercialization in world's second most populous country underway
NORCROSS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB:GTHP) reported today that the Company received Regulatory Approval from the Indian Ministry of Health & Family Welfare to allow commercialization of the LuViva device and disposables. The Ministry concluded that the LuViva device is "Non Invasive" and as such is "not regulated under the Drugs and Cosmetics Act 1940 and Medical Device Rules 2017 thereunder." As a result, LuViva can now be commercialized in India.
"There are approximately 330 million women who are age appropriate for cervical cancer screening in India," said Gene Cartwright, CEO. "Only a small percentage of age appropriate women are screened today in India due to the logistical complications of using other methods of cervical cancer screening. LuViva is an attractive alternative because it doesn't require a patient sample or a laboratory, and a result is given in approximately 1 minute at the point of care."
Letter of Intent with DSS Imagetech (DSS) for potential distribution of LuViva in India. DSS is based in New Delhi, has 150 employees and distributes products from Abbott Labs and Olympus. DSS Image has committed to conducting further market research and Guided Therapeutics has committed to further training and travel with the intent of signing a distribution agreement in or before Q2 2018.
4. INDONESIA
"The firm’s LuViva Advanced Cervical scan has recently begun routine use in Indonesia. The Indonesian distributor had made a request for a total of 10 LuViva devices along with four thousand disposables in at the end of last year."
Guided Therapeutics Ships 8 LuViva Devices and 4,500 Single Use Cervical Guides to Indonesia in Q4 2017
GTHP reported today record sales for a quarter in Indonesia, with eight LuViva® Advanced Cervical Scans shipped in the fourth quarter of last year. In addition, Indonesia ordered 4,500 single-use Cervical Guides which were shipped along with the LuViva devices. The increase in orders of high-margin Cervical Guides indicates that installed LuViva units are beginning to see greater usage in hospitals and clinics. Based on previous studies and evaluations of LuViva, medical researchers in Indonesia are recommending the LuViva test as an alternative to the Pap test for cervical cancer screening.
LUVIVA IS ALSO BEING SOLD TO THESE COUNTRIES ALSO!~
Health Canada approved 2012
Singapore Health Authority approved 2012
European CE Mark approved 2013
Mexican COFEPRIS approved 2014
Kenya
Nigeria
Costa Rica
Guatemala
Saudi Arabia
Kuwait
UAE
Chile
There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide. The world market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020.
Guided Therapeutics currently has distributors in the following territories:
ASIA:
Afganistan
Azerbaijan
Bangladesh
Georgia
Indonesia
India
Kazakhstan
Korea
Kyrgyzstan
Malaysia
Nigeria
Russia
Slovakia
Tajikistan
Turkmenistan
Uzbekistan
EUROPE:
Armenia
Belgium
Cyprus
Czech Republic
Estonia
Finland
France
Italy
Luxemburg
Netherlands
Turkey
UK
AFRICA:
Algeria
Egypt
Jordan
Kenya
Lebanon
Libya
Malawi
Morocco
Sudan
Tunisia
Uganda
SOUTH AMERICA:
Brazil
Chile
Guatemala
NORTH AMERICA:
Canada
Mexico
MIDDLE EAST:
Iran
Iraq
Saudi Arabia
Kuwait
Oman
Syria
Qatar
UAE
Yemen
http://myluviva.com/intl/distributors-international/
$GTHP
Recent GTHP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 06:36:25 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/20/2024 06:42:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 06:48:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 04:24:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 08:28:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2023 09:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2023 04:44:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/07/2023 07:53:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 07:00:31 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM